The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review.

Interleukin-7 (IL-7) is essential for maintaining the immune system's defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans. In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa). However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas.

[1]  A. Badou,et al.  Deciphering immune microenvironment and cell evasion mechanisms in human gliomas , 2023, Frontiers in Oncology.

[2]  Ziwen Liu,et al.  Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy , 2023, Frontiers in Immunology.

[3]  Lei Zhao,et al.  GM‐CSF and IL‐7 fusion cytokine engineered tumor vaccine generates long‐term Th‐17 memory cells and increases overall survival in aged syngeneic mouse models of glioblastoma , 2023, Aging cell.

[4]  R. Bellamkonda,et al.  IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma , 2023, Frontiers in Immunology.

[5]  T. Choueiri,et al.  IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma , 2022, Nature Medicine.

[6]  A. Osipov,et al.  The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance , 2022, International journal of molecular sciences.

[7]  Se-Hwan Yang,et al.  A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions , 2022, Blood advances.

[8]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. , 2022, Neuro-oncology.

[9]  I. Jang,et al.  The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy , 2022, International journal of molecular sciences.

[10]  Bence Galik,et al.  Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma , 2022, Biomedicines.

[11]  S. Abubakar,et al.  Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment , 2022, Frontiers in Immunology.

[12]  F. Gao,et al.  A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity , 2022, Nature Communications.

[13]  Yu Fu,et al.  Interferon-α and its effects on cancer cell apoptosis , 2022, Oncology letters.

[14]  C. Urueña,et al.  CAR-T Cell Performance: How to Improve Their Persistence? , 2022, Frontiers in Immunology.

[15]  M. Robertson,et al.  Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives , 2022, Frontiers in Immunology.

[16]  Xinna Deng,et al.  Folate Receptor-Alpha Targeted 7x19 CAR-γδT Suppressed Triple-Negative Breast Cancer Xenograft Model in Mice , 2022, Journal of oncology.

[17]  Chufeng Liu,et al.  IL-7-Treated Periodontal Ligament Cells Regulate Local Immune Homeostasis by Modulating Treg/Th17 Cell Polarization , 2022, Frontiers in Medicine.

[18]  Y. Sung,et al.  Compassionate use of recombinant human IL‐7‐hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma , 2022, medRxiv.

[19]  R. Jia,et al.  The Broad Immunomodulatory Effects of IL-7 and Its Application In Vaccines , 2021, Frontiers in Immunology.

[20]  Hai Deng,et al.  Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis , 2021, Frontiers in Immunology.

[21]  U. Höpken,et al.  Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages , 2021, Molecular therapy. Methods & clinical development.

[22]  Jingting Jiang,et al.  The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy , 2021, Frontiers in Cell and Developmental Biology.

[23]  Jie-Young Song,et al.  TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma , 2021, International journal of molecular sciences.

[24]  H. Maecker,et al.  IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) , 2021, Journal for ImmunoTherapy of Cancer.

[25]  B. Kwon,et al.  IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model , 2021, Cells.

[26]  Baoxia Liang,et al.  IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin , 2021, Journal of Hematology & Oncology.

[27]  M. Nishimura,et al.  Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response , 2021, Scientific Reports.

[28]  N. LaRusso,et al.  An aged immune system drives senescence and ageing of solid organs , 2021, Nature.

[29]  Y. Arai,et al.  IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors , 2021, Cancer Immunology, Immunotherapy.

[30]  S. Beck,et al.  Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion , 2021, Cell.

[31]  L. Conti,et al.  The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy , 2021, Frontiers in Oncology.

[32]  Lisa M. Ebert,et al.  The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy , 2021, Cells.

[33]  B. Zhu,et al.  Id3 and Bcl6 Promote the Development of Long-Term Immune Memory Induced by Tuberculosis Subunit Vaccine , 2021, Vaccines.

[34]  P. Dasgupta,et al.  IL-15 Upregulates Telomerase Expression and Potently Increases Proliferative Capacity of NK, NKT-Like, and CD8 T Cells , 2021, Frontiers in Immunology.

[35]  A. Tong,et al.  Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma , 2020, Cancer Immunology, Immunotherapy.

[36]  R. Richardson,et al.  Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis , 2020, International journal of molecular sciences.

[37]  Zhichen Sun,et al.  Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. , 2020, JCI insight.

[38]  G. Mcinerney,et al.  Activation of the PI3K-AKT Pathway by Old World Alphaviruses , 2020, Cells.

[39]  Y. Arai,et al.  Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade , 2020, Science Translational Medicine.

[40]  P. Vidal.  Interferon α in cancer immunoediting: From elimination to escape , 2020, Scandinavian journal of immunology.

[41]  R. Abdi,et al.  T Regulatory Cells and Priming the Suppressive Tumor Microenvironment , 2019, Front. Immunol..

[42]  A. Othman,et al.  Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib , 2019, Journal of clinical pharmacology.

[43]  S. Walsh,et al.  New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models , 2019, Leukemia.

[44]  Christopher M. Jackson,et al.  Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.

[45]  J. Barata,et al.  Flip the coin: IL-7 and IL-7R in health and disease , 2019, Nature Immunology.

[46]  F. Han,et al.  The Akt/FoxO/p27Kip1 axis contributes to the anti‐proliferation of pentoxifylline in hypertrophic scars , 2019, Journal of cellular and molecular medicine.

[47]  I. Kang,et al.  Interleukin-7 Contributes to the Invasiveness of Prostate Cancer Cells by Promoting Epithelial–Mesenchymal Transition , 2019, Scientific Reports.

[48]  M. Caligiuri,et al.  Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  J. Barata,et al.  A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia , 2019, Leukemia.

[50]  J. Barata,et al.  IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update , 2019, Advances in biological regulation.

[51]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[52]  S. Durum,et al.  Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations , 2018, Oncotarget.

[53]  K. Tamada,et al.  IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor , 2018, Nature Biotechnology.

[54]  Y. Matsumura,et al.  Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease , 2017, Scientific Reports.

[55]  Jianzhu Chen,et al.  Interleukins 7 and 15 Maintain Human T Cell Proliferative Capacity through STAT5 Signaling , 2016, PloS one.

[56]  N. Deng,et al.  IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF-κB pathway. , 2016, International immunopharmacology.

[57]  G. Esendagli,et al.  The untold story of IFN-γ in cancer biology. , 2016, Cytokine & growth factor reviews.

[58]  Mercedes Soares-Silva,et al.  The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids , 2016, Front. Microbiol..

[59]  G. Bergers,et al.  Glioblastoma: Defining Tumor Niches. , 2015, Trends in cancer.

[60]  J. Soulier,et al.  Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia , 2015, Haematologica.

[61]  Paul Shinn,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[62]  Y. Wan,et al.  Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy , 2015, International journal of molecular sciences.

[63]  F. Speleman,et al.  ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[64]  B. Becher,et al.  New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.

[65]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[66]  F. Gouilleux,et al.  IL-2 Phosphorylates STAT5 To Drive IFN-γ Production and Activation of Human Dendritic Cells , 2014, The Journal of Immunology.

[67]  W. Leonard,et al.  Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.

[68]  Y. Wan,et al.  IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model. , 2014, Immunology letters.

[69]  M. Jakóbisiak,et al.  Interleukin 12: still a promising candidate for tumor immunotherapy? , 2014, Cancer Immunology, Immunotherapy.

[70]  P. Ascierto,et al.  Interleukin 18: friend or foe in cancer. , 2013, Biochimica et biophysica acta.

[71]  P. Siesjö,et al.  IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models , 2013, Journal of Neuroimmunology.

[72]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[73]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[74]  N. Gray,et al.  Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors , 2012, Leukemia.

[75]  C. Paige,et al.  The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. , 2012, Seminars in immunology.

[76]  F. Chiodi,et al.  IL-7 modulates B cells survival and activation by inducing BAFF and CD70 expression in T cells. , 2012, Journal of autoimmunity.

[77]  F. Lafeber,et al.  Interleukin-7: a key mediator in T cell-driven autoimmunity, inflammation, and tissue destruction. , 2012, Current pharmaceutical design.

[78]  H. Ng,et al.  Overexpression of IL-7 enhances cisplatin resistance in glioma , 2012, Cancer biology & therapy.

[79]  A. Ferrando,et al.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia , 2011, Nature Genetics.

[80]  E. Wang,et al.  Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer , 2011, Cancer Immunology, Immunotherapy.

[81]  S. Ferrini,et al.  Role of Common-Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for Immunotherapy , 2011, Journal of biomedicine & biotechnology.

[82]  A. Khaled,et al.  Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the hexokinase II gene. , 2010, American journal of physiology. Cell physiology.

[83]  Se-Hwan Yang,et al.  Marked enhancement of antigen‐specific T‐cell responses by IL‐7‐fused nonlytic, but not lytic, Fc as a genetic adjuvant , 2010, European journal of immunology.

[84]  P. Siesjö,et al.  Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNγ-transduced tumor cell immunotherapy of experimental glioma , 2010, Journal of Neuroimmunology.

[85]  E. Klein,et al.  Interleukin 7 enhances the proliferation and effector function of tumor‐infiltrating lymphocytes from renal‐cell carcinoma , 2009, International journal of cancer.

[86]  T. Mak,et al.  Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.

[87]  S. Kim-Schulze,et al.  Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[89]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[90]  J. Rathmell,et al.  IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. , 2008, Blood.

[91]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[92]  P. Kaldis,et al.  IL-7 promotes T cell proliferation through destabilization of p27Kip1 , 2006, The Journal of experimental medicine.

[93]  T. Fry,et al.  The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance , 2005, The Journal of Immunology.

[94]  G. Watkins,et al.  Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo , 2005, The British journal of surgery.

[95]  A. Singer,et al.  IL-7 Receptor Signals Inhibit Expression of Transcription Factors TCF-1, LEF-1, and RORγt , 2004, The Journal of experimental medicine.

[96]  M. Huang,et al.  Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2003, Human gene therapy.

[97]  Leo Lefrançois,et al.  Cytokine control of memory T-cell development and survival , 2003, Nature Reviews Immunology.

[98]  Qing Yu,et al.  In Vitro Evidence That Cytokine Receptor Signals Are Required for Differentiation of Double Positive Thymocytes into Functionally Mature CD8+ T Cells , 2003, The Journal of experimental medicine.

[99]  A. Khaled,et al.  Lymphocide: cytokines and the control of lymphoid homeostasis , 2002, Nature Reviews Immunology.

[100]  G. R. Davies,et al.  Interleukins 7 and 12 are expressed in head and neck squamous cancer. , 2001, Clinical otolaryngology and allied sciences.

[101]  Richard Murray,et al.  IL-7 is critical for homeostatic proliferation and survival of naïve T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[102]  K. Aozasa,et al.  Expression of Interleukin-7 and Its Receptor in Thyroid Lymphoma , 2000, Laboratory Investigation.

[103]  L. Lu,et al.  Regulation of cell survival during B lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone marrow of mice with altered expression of IL-7 and recombinase-activating gene-2. , 1999, Journal of immunology.

[104]  A. Riddell,et al.  Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor , 1998, Nature.

[105]  L. Rawlinson,et al.  T Cell Proliferation in Response to Interleukins 2 and 7 Requires p38MAP Kinase Activation* , 1997, The Journal of Biological Chemistry.

[106]  N. Iizuka,et al.  Cytokine mRNA expression patterns in human esophageal cancer cell lines. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[107]  A. Venkitaraman,et al.  Interleukin‐7 induces the association of phosphatidylinositol 3‐kinase with the α chain of the interleukin‐7 receptor , 1994, European journal of immunology.

[108]  M. Herlyn,et al.  Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes , 1994, International journal of cancer.

[109]  T. Marunouchi,et al.  Expression of cytokine receptors in cultured neuronal and glial cells , 1993, Neuroscience Letters.

[110]  J. Frishman,et al.  Genes for Interleukin 7 Are Transcribed in Leukemic Cell Subsets of Hdividuak with Chronic Lymphocytic Leukemia , 1993 .

[111]  P. Leder,et al.  Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice , 1993, The Journal of experimental medicine.

[112]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[113]  S. Ziegler,et al.  Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes , 1991, The Journal of experimental medicine.

[114]  J. Blay,et al.  ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  P. Siesjö,et al.  Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cells , 1999, Cancer Gene Therapy.

[116]  W. Leonard,et al.  Signaling via the IL-2 and IL-7 receptors from the membrane to the nucleus. , 1999, Cold Spring Harbor symposia on quantitative biology.